Correspondence 0001213900-24-023386 from Cadrenal Therapeutics, Inc. (CVKD)
Cadrenal Therapeutics, Inc.
Date: March 18, 2024 · CIK: 0001937993 · Accession: 0001213900-24-023386
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-277835
Letter
VIA EDGAR United States Securities Division of Corporation Finance Registration Statement on Form S-3 Filed March 12, 2024 File No: 333-277835
Re: Cadrenal Therapeutics, Inc.
Dear Sir or Madam:
Cadrenal Therapeutics, Inc. (the “Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3, as amended (File No. 333-277835), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to become effective on Wednesday, March 20, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes Leslie Marlow and/or Jamie Plisner of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow at (212) 885-5358 or Ms. Plisner at (212) 885-5298 with any questions you may have concerning this request, and please notify either of them when this request for acceleration has been granted.
Thank you.
Very truly yours,
CADRENAL THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
March 18, 2023
VIA EDGAR
United States Securities
and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re:
Cadrenal Therapeutics, Inc.
Registration Statement on Form S-3
Filed March 12, 2024
File No: 333-277835
Dear Sir or Madam:
Cadrenal Therapeutics, Inc. (the
“Registrant”) hereby requests that the effective date of the above-referenced Registration Statement on Form S-3, as
amended (File No. 333-277835), be accelerated by the U.S. Securities and Exchange Commission (the “Commission”) to
become effective on Wednesday, March 20, 2024, at 5:00 p.m., Eastern Time, or as soon as reasonably practicable thereafter.
The Registrant understands
that the Staff of the Commission will consider this request as confirmation by the Registrant that it is aware of its responsibilities
under the federal securities laws as they relate to the issuance of the securities covered by the Registration Statement.
The Registrant hereby authorizes
Leslie Marlow and/or Jamie Plisner of Blank Rome LLP to orally modify or withdraw this request for acceleration. Please contact Ms. Marlow
at (212) 885-5358 or Ms. Plisner at (212) 885-5298 with any questions you may have concerning this request, and please notify either of
them when this request for acceleration has been granted.
Thank you.
Very truly yours,
CADRENAL THERAPEUTICS, INC.
By:
/s/ Quang Pham
Name:
Quang Pham
Title:
Chief Executive Officer
cc: Leslie Marlow, Blank Rome LLP
Jamie Plisner, Blank Rome LLP